About Genomas
Genomas is a company based in United States founded in 2003 was acquired by Rennova Health in September 2016.. Genomas has raised $4 million across 17 funding rounds from investors including Rennova Health, NIH and HHS. Genomas operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Genomas Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4 M (USD)
in 17 rounds
-
Latest Funding Round
$2.15 M (USD), Grant
Sep 10, 2013
-
Investors
Rennova Health
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Rennova Health
(Sep 29, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genomas
Genomas has successfully raised a total of $4M across 17 strategic funding rounds. The most recent funding activity was a Grant round of $2.15 million completed in September 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 17
- Last Round Grant — $2.2M
-
First Round
First Round
(01 Feb 2005)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2013 | Amount | Grant - Genomas | Valuation |
investors |
|
| Jun, 2011 | Amount | Grant - Genomas | Valuation |
investors |
|
| Sep, 2009 | Amount | Grant - Genomas | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genomas
Genomas has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Rennova Health, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Federal innovation and scientific achievement services are provided.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genomas
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genomas
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genomas Comparisons
Competitors of Genomas
Genomas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Diagnostic services are provided through laboratories and radiology units.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Genomas
When was Genomas founded?
Genomas was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Where is Genomas located?
Genomas is headquartered in United States.
Is Genomas a funded company?
Genomas is a funded company, having raised a total of $4M across 17 funding rounds to date. The company's 1st funding round was a Grant of $1.4M, raised on Feb 01, 2005.
What does Genomas do?
Developer of treatments for CNS disorders and metabolic diseases. Its proprietary PhyzioGenomics technology uses the database that consists of genomic information of over 6000 individuals to connect genetic variations to physiologic changes. Its flagship product HILOmet PhyzioType is indicated for determining treatment regimens for neuropsychiatric and cardiometabolic diseases. In addition, it is developing similar products for antipsychotics, statins, and anti-diabetic drugs.
Who are the top competitors of Genomas?
Genomas's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Who are Genomas's investors?
Genomas has 5 investors. Key investors include Rennova Health, NIH, HHS, SBIR, and Hartford Hospital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.